Clinical evaluation of determinants of glycemic control. A new approach using serum glucose, C-peptide, and body mass indexes in type II diabetic patients.
We evaluated the clinical characteristics and relationships between values of serum glucose, C-peptide, and body mass index (BMI) in 40 type II diabetic patients. Patients were divided into three groups according to the drug therapy: group A (n=16), oral sulfonylurea agent; group B (n=16), insulin alone; and group C (n=8), combined insulin and oral agent. The relationships between the various factors were expressed as ratios (C-peptide/BMI, glucose/BMI, and C-peptide/glucose scores). Using glycosylated hemoglobin (HbA1) value of less than 10.5% to denote response to therapy, each group was subdivided into responders and nonresponders. Comparing the data in group A, mean (+/-SEM) fasting serum glucose levels were significantly lower in responders vs nonresponders. The mean HbA1 levels were 8.59+/-0.54% vs 1 2.34+/-0.34%, respectively. The C-peptide/BMI scores were 7.4+/-1.0 vs 8.14+/-1.2; C-peptide/glucose scores, 1.73+/-0.27 vs 0.81+/-0.12; and glucose/BMI scores, 493+/-54 vs 1,082+/-168, respectively. The responders and nonresponders in group B had values similar to those of group A. Group C patients had data A and B. The responders in each group were characterized by serum glucose levels less than 200 mg/dL, C-peptide/glucose score greater than 1, and glucose/BMI score less than 700. T he 200 mg/dL, C-peptide/glucose score less than 1, and glucose/BMI score greater than 700. These simple calculated scores validate the importance of glucose/C-peptide/BMI interrelationships in ambulatory diabetic patients.